Barbasco: A Comprehensive Reference
1. Identity and Nomenclature
1.1 The Name "Barbasco" — Multiple Plants, One Word
"Barbasco" is the common name of several distinct plants that contain bioactive chemical compounds historically exploited by indigenous populations of the Americas. The plants most commonly designated by this term include Lonchocarpus urucu (used by the Shuar and Nukak peoples as a fish poison), Deguelia utilis (used in Brazil and Peru for fishing), Jacquinia barbasco (an evergreen shrub), and one or more inedible wild Mexican yams — principally Dioscorea mexicana and Dioscorea composita — from which progesterone can be synthesized. This article focuses primarily on the Dioscorea-genus plants, which are the most widely referenced in the supplement, pharmaceutical, and scientific literature under the barbasco name, as well as Dioscorea villosa (wild yam), which shares many common names and constituents and whose botanical and clinical literature is deeply intertwined with that of Mexican barbasco.
1.2 Botanical Identity — Mexican Barbasco (Dioscorea composita and D. mexicana)
Dioscorea composita, or barbasco, is a species of yam in the family Dioscoreaceae, native to Mexico. It is notable for its role in the production of diosgenin, which is a precursor for the synthesis of hormones such as progesterone. Dioscorea mexicana — also called "cabeza de negro" — is a caudiciform member of the same genus, possessing a partly to completely above-ground, dome-shaped caudex with a thick woody outer layer up to 3 feet (90 cm) in diameter and 8–10 inches in height, its surface divided into regular polygonal plates that become protuberant with age. Vigorous annual vines may reach 30 feet (9 m) before dying back in winter; the vines bear heart-shaped leaves. The species ranges from San Luis Potosà in northeastern Mexico south to Panama.
Marker also discovered that the composita variety had a much higher content of diosgenin than the mexicana variety, and therefore it came to replace the latter in the production of synthetic hormones. The plant has a subterranean stem, or rhizome, that resembles a tortoise shell and produces heart-shaped leaves.
1.3 Botanical Identity — Wild Yam / Barbasco (Dioscorea villosa)
Dioscorea villosa is a perennial plant with tuberous roots that grow wild in North America, near lakes, swamps, humid forests, and hillsides. It grows at altitudes from sea level to 1,500 m and is a climbing plant with thin stems up to 3 m in length. Its scientific name refers to the Greek physician Dioscorides, while "villosa" refers to the rough hairs on the leaves. There are over 600 species of yam (Dioscorea spp.), with wild yam believed to be native to North America.
Synonyms of Dioscorea villosa include Dioscorea hirticaulis and Dioscorea villosa var. hirticaulis. Common names include wild yam, Atlantic yam, common wild yam, wild yam-root, yellow yam, colic root, and rheumatism root. Additional names applied in commerce and herbalism include barbasco, batata silvestre, black yam, China root, devil's bones, Dioscorea barbasco, Mexican yam, natural DHEA, rheumatism root, and yuma.
1.4 Other Plants Named Barbasco
Jacquinia barbasco (syn. Jacquinia arborea) is a shrub or small tree of tropical America and is the source of a substance used to stun fish so they can be caught easily — a substance described as poisonous to fish but harmless to humans. Jacquinia pungens (syn. Jacquinia macrocarpa subsp. pungens) is a species of flowering plant in the family Primulaceae, native to southern Mexico. It is a shrub growing to 4 m tall, with lanceolate to oblong evergreen leaves 4–7 cm long with a sharply pointed apex; its flowers are yellow, orange, or red, produced in tight racemes; the fruit is a yellow berry. These species are not closely related to the Dioscorea yams and are considered distinct plants in phytochemical and pharmacological literature.
1.5 Common Preparations and Forms
In the supplement market, products sold under the names "barbasco," "wild yam," or "Mexican wild yam" are derived primarily from the dried root and rhizome of Dioscorea villosa or related species. Wild yam extract is sold as a dietary supplement, liquid extract, or cream. One species, Dioscorea villosa — otherwise known as the Mexican wild yam — is a tuberous plant that produces a thick, starchy underground rhizome; it is this root that is used in many herbal remedies, in both nutritional and medicinal products. The wild yam is marketed as an herbal remedy for menstrual discomfort and menopausal symptoms, and is typically promoted as an alternative to hormone replacement therapy (HRT). In the industrial context, the Mexican barbasco trade centered on the diosgenin-rich yam species Dioscorea mexicana, Dioscorea floribunda, and Dioscorea composita; Mexican campesinos harvested the root in the jungle, selling it to middlemen who brought it to processing plants where the root was fermented and the diosgenin extracted.
2. Traditional and Historical Use
2.1 Indigenous Mesoamerican Use
Before becoming used industrially, the tuber was used by Chinantec healers in northern Oaxaca as an abortifacient and in cures for aching joints. It was also used by Chinantecs as a poison for fishing in the Papaloapan river. In Mexico, indigenous Zoque people annually introduced barbasco, a fish toxicant, into the Cueva del Azufre cave to harvest fish during a religious ceremony — a ritual documented in peer-reviewed biology research.
The story about the plant behind the multi-million pharmaceutical discovery, Dioscorea composita or barbasco, remains poorly known. Even when botanists Michael Joseph François Scheidweiler had described D. mexicana in Brussels in 1837 and William Botting Hemsley described D. composita in London in 1884, both from plants obtained in Mexico, the chemical properties of Dioscorea plants were only known among locals who used them for fishing, as it is toxic for fish, but not for mammals.
In traditional medicine, barbasco is used as an antispasmodic and to treat various ailments including arthritis, rheumatic fevers, inflammation of the sciatic nerve, pain in pregnant women, diarrhoea, haemorrhoids, colic, ulcers, and diabetes.
2.2 Native North American Use (Dioscorea villosa)
Dioscorea villosa has a long history of use among Native American tribes, particularly the Cherokee and Iroquois, who prepared decoctions from the rhizome to address various ailments. These preparations were employed to alleviate colic, menstrual cramps, rheumatism, and digestive issues such as gastric distress and intestinal irritation. For instance, the Cherokee used root decoctions in combination with other plants to treat overeating-related stomach problems and as an emetic for conditions believed to stem from snake poison or supernatural causes.
In 19th-century herbalism, especially within the Eclectic medical tradition, D. villosa gained prominence as an antispasmodic remedy for smooth muscle spasms, including those associated with bilious colic, dysmenorrhea, and abdominal neuroses. Eclectic physicians valued it for relieving pain from gastrointestinal irritation, nausea of pregnancy, and rheumatic conditions.
Some of the English common names of this plant reflect its use in Native American and other traditional medicines. Native Americans in the southeast cultivated this plant. In traditional Russian herbal medicine, saponin extracts from the roots of various varieties of wild yam are thought to be an anticoagulant, antisclerotic, antispasmodic, cholagogue, depurative, diaphoretic, diuretic, and a vasodilator.
2.3 The 20th-Century Pharmaceutical Trade
During the 1930s, dubbed the Decade of Sex Hormones, chemists determined the structure of progesterone and started using it as a medical treatment for menstrual complications. In 1941, in the state of Veracruz, Russell Marker discovered a plant of the Dioscorea genus (D. bartlettii), popularly known as "cabeza de negro," whose rhizome became a source of diosgenin in 1942. He succeeded in converting diosgenin into progesterone, and by 1943, having settled in Mexico and independently produced more than 1 kg of progesterone — then worth over one hundred thousand U.S. dollars on the market — he partnered with others to found Syntex, S.A. in Mexico City in January 1944.
In 1949, Marker learned of a close relative of D. mexicana: D. composita, known as barbasco among locals in Veracruz. The plant soon became the industry's favourite source of diosgenin because it had five times more of the substance than D. mexicana.
By 1951, Syntex researchers, building on Marker's work, synthesized norethindrone — the active ingredient in the first oral contraceptive — from diosgenin derived initially from D. mexicana. Barbasco proved an even greater boon when chemists at Upjohn discovered how to use an enzyme to attach an additional oxygen atom to the molecule, enabling them to produce cortisone and all of its derivatives from diosgenin. Thus, barbasco not only yielded progesterone for birth control pills but could be synthesized into cortisone, another chemical that revolutionized medicine.
By the mid-1970s, 125,000 Mexican peasants depended on the barbasco trade for their livelihood, and ten tons of barbasco per week were extracted from the wild.
3. Key Constituents and Active Compounds
3.1 Diosgenin — The Primary Steroidal Sapogenin
Diosgenin is a well-known steroid sapogenin derived from plants and has been used as a starting material for the production of steroidal hormones. Diosgenin is a plant steroid found in the rhizomes of plants of the genus Dioscorea and was key to developing the contraceptive pill in Mexico in 1951. Marker had been characterizing saponins — steroidal glycosides that, upon hydrolysis, release an aglycone commonly referred to as a sapogenin — with his work focused on using diosgenin as a feedstock for the production of steroid hormones. The name "diosgenin" combines the plant genus from which it is obtained, Dioscorea, with the class of compound, a sapogenin.
Diosgenin serves as a key precursor in the synthesis of various steroid hormones, including progesterone, cortisol, and components of contraceptive formulations, through the Marker degradation process — a chemical transformation that converts the sapogenin into pregnenolone and subsequently other steroids.
3.2 The Human-Conversion Misconception
Diosgenin, the saponin extracted from Dioscorea villosa (wild yam), does not bind to the human estrogen or progesterone receptor in vitro and cannot be converted in the human body to progesterone. Diosgenin has been promoted as a natural form of DHEA, yet the chemical reaction needed to convert diosgenin into DHEA is not known to occur in the human body. Ingesting the yam extract has not been found to increase DHEA levels in humans.
3.3 Other Identified Constituents
Constituents of wild yam include steroidal saponins (including dioscin and trillin, which yield diosgenin), phytosterols, alkaloids including dioscorine, tannins, and starch. Specifically documented chemical constituents include steroidal saponins (diosgenin and dioscin), proteins (dioscorin) and starch, alkaloids (dioscorine and dihydrodioscorine), and tannins.
3.4 Mechanisms of Action — Preclinical Evidence
Diosgenin has shown a vast range of pharmacological activities in preclinical studies. It exhibits anticancer, cardiovascular protective, anti-diabetes, neuroprotective, immunomodulatory, estrogenic, and skin protective effects, mainly by inducing apoptosis, suppressing malignant transformation, decreasing oxidative stress, preventing inflammatory events, promoting cellular differentiation/proliferation, and regulating T-cell immune response.
Anti-inflammatory pathways: Based on its modulatory impact on the NF-κB pathway, diosgenin supplementation is associated with downregulation of the NF-κB pathway and TGF-β, resulting in inhibition of inflammation. Diosgenin significantly reduces the secretion of different inflammatory factors including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 via upregulation of glucocorticoid receptors, secretory leukocyte protease inhibitor, glucocorticoid-induced leucine zipper, mitogen-activated protein kinases (MAPK) phosphatase 1, and downregulation of heat shock proteins (HSP70).
Anticancer pathways: Diosgenin interferes with cell death pathways and their regulators to induce apoptosis. It antagonizes tumor metastasis by modulating epithelial–mesenchymal transition and actin cytoskeleton to change cellular motility and suppressing degradation of the matrix barrier. Its anti-inflammatory activity is through inhibiting production of pro-inflammatory cytokines, enzymes, and adhesion molecules.
Cardiovascular/lipid pathways: The antiatherosclerosis potential of diosgenin and its derivatives has been studied. Diosgenin treatment significantly enhanced the expression of ATP-binding cassette transporter A1 (ABCA1) protein without any effect on liver X receptor α levels. Additionally, diosgenin treatment also inhibits aortic atherosclerosis progression via downregulation of miR-19b proteins in THP-1 macrophages/MPM-derived foam cells.
Neuroprotective pathways: As a natural antioxidant, diosgenin is known to have neuroprotective effects and to improve some aging-related deficits, namely memory improvement. This steroid has potential interest in neuropathies such as neurodegenerative diseases including Alzheimer's disease. The diosgenin-induced cognitive enhancement in normal mouse neurons is mediated by the membrane-associated rapid response steroid-binding receptor (1,25D3-MARRS).
Estrogenic signaling: Diosgenin drives cellular growth/differentiation through the estrogen receptor (ER) cascade and transcriptional factor PPARγ. However, as noted, classical direct binding to estrogen receptors at physiological concentrations has not been confirmed in human tissue.
4. Scientific Evidence by Area of Use
4.1 Menopausal Symptoms
Clinical evidence: Many women seek alternatives to hormonal therapies for the management of menopausal symptoms. Among treatments popular are extracts of wild yam (Dioscorea villosa), applied topically in the form of cream. These preparations are known to contain steroidal saponins, including diosgenin, which has been claimed to influence endogenous steroidogenesis. A double-blind, placebo-controlled, cross-over study was conducted in 23 healthy women suffering from troublesome symptoms of the menopause. After a 4-week baseline period, each woman was given active cream and matching placebo for 3 months in random order. Both study groups showed minimal improvement on flushing severity and number with no significant difference between wild yam extract and placebo.
Small studies on whether wild yam can relieve menopausal symptoms are mixed: one suggested that an oral D. alata formula was more effective than placebo, but another showed a topical D. villosa formula was ineffective. In other small studies, an oral diosgenin-rich yam extract appeared to enhance cognitive function, and sex hormone and lipid profiles appeared to improve with dietary yam intake. However, larger studies are needed to confirm whether wild yam in any form actually has any benefits for menopausal symptoms.
The Society of Obstetricians and Gynaecologists of Canada's revised clinical practice guidelines (2021) on managing menopausal vasomotor symptoms do not recommend wild yam for reducing menopausal symptoms based on a lack of evidence to support clinical benefit. Likewise, the Endocrine Society clinical practice guidelines for the treatment of symptoms of the menopause (2015) recommend counseling patients on the lack of consistent evidence for benefit of complementary medicine therapies, including wild yam.
Evidence strength: Weak. The most rigorous human trial (double-blind, crossover, n=23) found no significant benefit. Two major specialty guideline bodies explicitly do not recommend wild yam for menopausal symptoms.
4.2 Inflammation and Rheumatism
Preclinical evidence: In cell studies, diosgenin can inhibit the proliferation and migration of rheumatoid arthritis synovial cells, and can reduce the inflammatory response of RA synovial cells, during which the expression of PDE3B was significantly decreased. Due to the low toxicity of the herbal compounds, the risk of side effects of diosgenin for the management of inflammatory disorders such as asthma, rheumatism, rhinitis, and arthritis is considered lower than that of synthetic glucocorticoids — based on preclinical findings.
Evidence strength: Preliminary. Evidence is limited to in vitro and animal models. No adequately powered human clinical trials for inflammatory conditions have been identified in the peer-reviewed literature.
4.3 Cancer
Preclinical evidence: The steroid saponin diosgenin in wild yam modulates cell signaling involved in growth, differentiation, apoptosis, and oncogenesis. In vitro studies suggest wild yam extract protects against human breast cancer proliferation by acting as a weak phytoestrogen. In 2009, Srinivasan et al. reported a study on breast cancer cells where diosgenin was found to regulate survival of breast cancer cells via modulation of AKT, and this compound showed selective toxicity to the cancer cells without remarkably affecting normal epithelial cells of the breast (MCF-10A).
Future research will need to establish not only whether diosgenin is safe and efficacious as a chemopreventive agent against several human cancers, but also to develop and evaluate standards of evidence for health claims for diosgenin-containing foods.
Evidence strength: Preclinical only (in vitro and animal models). No human clinical trial evidence supports the use of barbasco or diosgenin in cancer prevention or treatment as of available sources.
4.4 Cardiovascular Disease and Atherosclerosis
Preclinical/mechanistic evidence: Literature search has resulted in in vitro, in vivo, and clinical trials that reported the efficacy of diosgenin and its analogs in modulating important molecular targets and signaling pathways such as PI3K/AKT/mTOR, JAK/STAT, NF-κB, MAPK, etc., which play a crucial role in the development of most diseases. It has been shown that regulation of NF-κB and oxidative stress signaling pathways by diosgenin is beneficial against cardiotoxicity induced by chemotherapeutic agents such as doxorubicin — in preclinical models.
Evidence strength: Primarily preclinical (in vitro and animal). Preclinical studies have shown promising effects on cancer, neuroprotection, atherosclerosis, asthma, bone health, and other pathologies. Clinical investigations have demonstrated diosgenin's nontoxic nature and promising benefits on cognitive function and menopause. However, further well-designed clinical trials are needed to address the other effects seen in preclinical studies.
4.5 Cognitive Function
Clinical evidence: As a natural antioxidant, diosgenin is known to have neuroprotective effects and to improve some aging-related deficits, including memory improvement. This steroid has potential interest in neuropathies such as neurodegenerative diseases, including Alzheimer's disease. Clinical investigations have demonstrated diosgenin's nontoxic nature and promising benefits on cognitive function and menopause. However, specific trial details (population size, design, outcome measures) from these studies were not fully recoverable from available sources; claims regarding cognitive benefit should therefore be considered preliminary pending further investigation.
A review of diosgenin and its derivatives as therapeutic agents for multiple neurological disorders discusses therapeutic efficacy for Parkinson's disease, Alzheimer's disease, brain injury, neuroinflammation, and ischemia. The review also critically evaluates existing limitations associated with the solubility and bioavailability of diosgenin and discusses imperatives for translational clinical research.
Evidence strength: Predominantly preclinical; limited and early-stage clinical signals. Large-scale human trials are lacking.
4.6 Diabetes and Blood Sugar Regulation
In preclinical studies, diosgenin exhibits anti-diabetes effects, among other pharmacological activities. Diosgenin has shown high potential and interest in the treatment of various disorders such as cancer, diabetes, arthritis, asthma, and cardiovascular disease. Research has reported that wild yams may help manage blood sugar due to the chemical called dioscoretine. Animal studies discovered that when rabbits with diabetes were administered dioscoretine derived from tubers, their blood sugar levels were reduced.
Evidence strength: Preclinical (animal studies); no human randomized controlled trial data identified for this indication specifically from barbasco/wild yam.
4.7 Bone Health
Dioscorea was found to increase bone mineral density in ovariectomised rats, but studies in humans are lacking. Preclinical research indicates potential relevance to osteoporosis through estrogen-pathway modulation, but this has not been replicated in human trials.
Evidence strength: Animal models only; no human evidence identified.
5. Body Systems Associated with Barbasco / Diosgenin
- Endocrine/reproductive system: Primary historical and commercial association (diosgenin as precursor for sex hormones and contraceptives); diosgenin itself does not bind human sex hormone receptors directly.
- Musculoskeletal system: Traditional use for rheumatism and joint pain; preclinical evidence for anti-inflammatory action in arthritis models.
- Gastrointestinal system: Traditional antispasmodic use for colic, intestinal cramps, and bilious conditions in the Eclectic and Native American traditions.
- Cardiovascular system: Preclinical evidence for antiatherosclerotic, antithrombotic, and lipid-modulating activity.
- Central nervous system: Preclinical and early clinical neuroprotective data; memory and cognitive studies ongoing.
- Metabolic system: Animal-model evidence for blood glucose modulation.
- Integumentary system: Applied topically in cosmetic creams; traditional use in skin preparations by some indigenous groups.
6. Dosage Forms and Reported Dosages
There are inadequate clinical trials on which to base dosing guidelines.
The following dosages are reported specifically as used in human or animal studies in the cited literature:
- In the Monash University double-blind crossover trial in 23 postmenopausal women, each subject was given active wild yam cream and matching placebo for 3 months in random order, after a 4-week baseline period. The specific concentration of active extract in the cream is not stated in available sources.
- One uncontrolled clinical study evaluated the effect of consuming 390 g of yam over 30 days.
- A clinical pilot study investigated a combination product containing nuciferine and diosgenin in the treatment of erectile dysfunction. A total of 143 candidates (ages 18–39 years) were selected and treated orally with nuciferine and diosgenin for up to three months (single dose, on alternative days). Specific per-dose quantities of diosgenin were not stated in available sources.
- In a rat pharmacokinetic study, the plasma concentration of an orally administered diosgenin formulation (cyclodextrin-bound) reached Cmax of 132.5 ± 48.2 ng/mL at 5.01 ± 0.55 h, with an AUC of 4121.9 ± 1354.7 ng·h/mL and an absolute oral bioavailability of 4.45 ± 1.46%.
- In an ovariectomized animal model, diosgenin administered at doses of 20 or 40 mg/kg for 15 days significantly stimulated the growth of the mammary epithelium.
- Animal studies examining endocrine-disrupting and reproductive toxicity used chronic exposure doses of 10, 50, 100, and 200 mg/kg following acute toxicity, repeated dose 90-day oral toxicity, and F1 extended one-generation reproductive toxicity protocols.
In topical cosmetic preparations, common concentrations are approximately 0.1–0.3% wild yam root extract in leave-on products (creams, lotions, serums). Historical maximum concentrations reported in industry documentation reached up to 15% extract in moisturizers, though such high levels are unusual now.
Several studies have reported poor bioavailability of diosgenin due to its strong hydrophobic nature and low aqueous solubility. As a substrate for P-glycoprotein, diosgenin also exhibits poor intestinal permeability and bioavailability. Pharmacokinetic studies have revealed that the total bioavailability of diosgenin is only about 7% in rats.
7. Safety Considerations and Interactions
7.1 General Tolerability
Clinical investigations have demonstrated diosgenin's nontoxic nature in the small number of human studies conducted to date. High doses of wild yam preparations may cause nausea, vomiting, and diarrhea. Possible allergic reactions, including rhinitis and dermatitis, have been documented. Although related to edible yams and sweet potatoes, wild yam (D. villosa) is not really edible; when consumed fresh, the underground rhizomes may cause nausea or other unpleasant side effects.
7.2 Genotoxicity and In Vitro Toxicity Signals
An in vitro study showed deleterious effects of diosgenin mediated via genetic instability. At concentrations greater than 30 μM, diosgenin reduced cell viability and increased micronucleus frequency. It also has a significant cytostatic effect. These findings are from cell studies and their relevance to human supplemental doses remains unclear.
It is important to be aware of the potential risks associated with diosgenin, as well as its potential to cause reproductive and endocrine toxicity. Research has evaluated the endocrine-disrupting and reproductive toxicity of diosgenin in albino mice using acute toxicity, repeated dose 90-day oral toxicity, and F1 extended one-generation reproductive toxicity study protocols.
7.3 Hormone-Sensitive Conditions
Caution is warranted in hormone-sensitive conditions such as breast cancer, diabetes, tendency to clot, and overt liver or kidney disease. Dioscorea could theoretically be given to women who have been treated for breast cancer, but safety data are required. The D. villosa species has been noted to induce chronic kidney injury via profibrotic pathways in animal models.
7.4 Potential Drug Interactions
Theoretical drug interactions identified in the clinical literature include: interaction with anticoagulants due to antiplatelet activity; interaction with anti-diabetic agents (as diosgenin may decrease blood sugar); possible increased risk of toxicity from hepatotoxic and nephrotoxic drugs; inhibition of anti-inflammatory effects of indomethacin/NSAIDs; and increased risk of adverse effects from estrogen or anti-estrogen medications. These interactions are characterised as theoretical rather than confirmed in clinical trials.
Theoretically, diosgenin can increase or decrease the effects of estrogens.
7.5 Bioavailability Limitation as a Safety Context
The main therapeutic limitations of diosgenin are represented by its low bioavailability; therefore, special emphasis is being paid to the production of nanoformulations or conjugate complexes to improve the compound's bioavailability. The low oral bioavailability (~4–7% in animal models) may inherently limit both the therapeutic and adverse effects of orally consumed barbasco preparations in humans, though this has not been formally studied in clinical safety trials.
7.6 Pregnancy and Lactation
Information regarding safety and efficacy in pregnancy and lactation is lacking. The documented traditional use of the plant as an abortifacient in Chinantec communities warrants caution regarding its use during pregnancy.
7.7 Adulteration and Labeling Concerns
Some wild yam products may contain synthetic progesterone, but the "wild yam" label can be misleading. This is a documented regulatory concern: products marketed as containing "natural" diosgenin or "wild yam" may have synthetic progesterone added without explicit disclosure, or may make claims about hormonal conversion that are scientifically unsupported.
8. Ecological and Conservation Context
According to science historian Gabriela Soto Laveaga at Harvard University, by 1959 — only fifteen years after Marker's rediscovery of barbasco — almost 30 million Dioscorea plants were collected in a single year. To keep the supply of diosgenin going, an army of more than 100,000 local peasants, known as barbasqueros, picked the plants from the wild. Dioscorea villosa is currently on the United Plant Savers "At Risk" list. The intensive collection of wild rhizomes generated sustainability challenges that continue to drive research into cultivated and biotechnological production of diosgenin.
References
Go back